Pneumocystis Jirovecii Genotyping
NCT06442345 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2025-06-27
Summary
We share our lives with microorganisms, and these generally do not pose a problem if an individual is healthy with a normal immune system. However, if the immune system was not functioning properly (e.g., cancer patients), they are at risk of infection. One microorganism, a fungus called Pneumocystis jirovecii (PCP), can cause severe chest infections in patients without properly functioning immune systems, leading to hospitalisation and death if untreated. If patients remain without a functioning immune system, they have a greater chance of repeated infection.
PCP spreads through air from person-to-person and can survive on environmental surfaces. Patients can be infected after contact with these surfaces. Hospitals have a responsibility to ensure PCP infected patients do not pass it on to other unwell patients. In cases where PCP has infected multiple patients, knowing if the same fungi has been passed along (or transmitted) from patient-to-patient is vital in understanding if there is an outbreak in the hospital. Understanding how similar (the relatedness) the PCP strain is allows healthcare workers to detect any transmission between patients or the environment.
To understand how related each patient's PCP infection is we will utilise a laboratory test called multilocus sequence typing (MLST). This test looks at sections of the fungi's genetic code using deoxyribonucleic acid (DNA) sequencing to create a code (genotype) which tells us how related one PCP is to others tested, allowing comparison between patients and ultimately spotting transmission.
Our aim is to develop this sequencing test using PCP positive patient samples and ensure it performs to high-quality standards. Surplus material from seventy known PCP positive patient samples will be tested. Each sample will be analysed to see if the DNA genotype matches or is similar to other patient samples we have tested, helping to understand how PCP may spread between patients.
Conditions
- Pneumocystis Pneumonia
Sponsors & Collaborators
-
Nottingham University Hospitals NHS Trust
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-30
- Primary Completion
- 2026-01-31
- Completion
- 2026-01-31
More Related Trials
-
Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
NCT06387667 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection
NCT00001701 ·Status: COMPLETED
-
Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.
NCT02333448 ·Status: COMPLETED
-
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
NCT05707156 ·Status: COMPLETED
-
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
NCT06510699 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Trial of Pulmonary Cryptococcosis in China
NCT02503449 ·Status: UNKNOWN
-
Fungal Infection Susceptibility
NCT00001352 ·Status: RECRUITING
-
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
NCT00002277 ·Status: COMPLETED ·Phase: PHASE3
-
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
NCT00238355 ·Status: TERMINATED ·Phase: PHASE2
-
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
NCT00689338 ·Status: COMPLETED ·Phase: PHASE3
-
Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095
NCT00177749 ·Status: TERMINATED ·Phase: PHASE4
-
Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?
NCT00786903 ·Status: COMPLETED
-
Pharmacokinetics of Voriconazole in Adult ECMO Patients
NCT04868188 ·Status: COMPLETED
-
Systemic Fungal Infections in ICU Patients
NCT03292224 ·Status: UNKNOWN
-
Evaluation of a Clinical Decision Support System for Fungal Infections
NCT05656157 ·Status: COMPLETED
-
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection
NCT00001702 ·Status: COMPLETED
-
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients
NCT03067350 ·Status: COMPLETED
-
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
NCT03717623 ·Status: RECRUITING ·Phase: PHASE4
-
Studies of Disorders With Increased Susceptibility to Fungal Infections
NCT01222741 ·Status: RECRUITING
-
Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients
NCT01419678 ·Status: COMPLETED ·Phase: NA
-
Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
NCT06137690 ·Status: RECRUITING
-
Itraconazole Therapy In Bronchiectasis With Airway Mold
NCT07283497 ·Status: RECRUITING ·Phase: PHASE4
-
Funguria in Hospitalized Patients
NCT00138502 ·Status: COMPLETED
-
Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients
NCT01907477 ·Status: COMPLETED ·Phase: NA
-
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
NCT00095316 ·Status: TERMINATED ·Phase: PHASE3